LIGAND PHARMACEUTICALS INCORPORATED (LGND) Unrealized Gain (Loss) on Derivatives

LIGAND PHARMACEUTICALS INCORPORATED Unrealized Gain (Loss) on Derivatives

LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Unrealized Gain (Loss) on Derivatives of $532.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Cash Flow › Operating Activities

us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-08-07

• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for the quarter ending 2026-06-30 was $1.37M.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for the quarter ending 2026-03-31 was -$837.00K.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for the quarter ending 2025-12-31 was $1.16M.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was $111.00K.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for fiscal 2025 was $1.02M.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for fiscal 2024 was -$20.01M, a 8104.00% decline from fiscal 2023.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for fiscal 2023 was $250.00K.
• LIGAND PHARMACEUTICALS INCORPORATED unrealized gain (loss) on derivatives for fiscal 2022 was $0.00.